Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19632958 | 1.00 | TMPRSS2 (0.35) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A | |
| SCHEMBL18480773 | 0.91 | TMPRSS2 (0.33) | TMPRSS2CDK5CDK5R1HSPA8 | |
| SCHEMBL18470920 | 0.91 | TMPRSS2 (0.33) | TMPRSS2CDK5CDK5R1HSPA8 | |
| SCHEMBL19636432 | 0.88 | TMPRSS2 (0.34) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A | |
| SCHEMBL15682921 | 0.88 | ADORA2A (0.34) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A | |
| SCHEMBL19632959 | 0.88 | TMPRSS2 (0.34) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A | |
| SCHEMBL15888888 | 0.88 | ADORA2A (0.34) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A | |
| SCHEMBL12393294 | 0.87 | ADORA2A (0.35) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A | |
| SCHEMBL19233543 | 0.86 | TMPRSS2 (0.33) | TMPRSS2CDK5CDK5R1 | |
| SCHEMBL881395 | 0.86 | TMPRSS2 (0.34) | TMPRSS2CDK5CDK5R1HSPA8ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334941-A1 | 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | EMORY UNIVERSITY | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334941-A1 | 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | HAVCR2, DERA, EIF2AK2 | TMPRSS2 2425/4885CDK5 4326/4885CDK5R1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.